Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

European Journal of Cancer

Volumn 51, Issue 11, 2015, Pages 1435-1443

  Puzanov, Igor ^a   Amaravadi, Ravi K ^b   McArthur, Grant A ^c   Flaherty, Keith T ^d   Chapman, Paul B ^e   Sosman, Jeffrey A ^a   Ribas, Antoni ^f   Shackleton, Mark ^c   Hwu, Patrick ^g   Chmielowski, Bartosz ^f   Nolop, Keith B ^h   Lin, Paul S ^h   Kim, Kevin B ^g,i  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h PLEXXIKON INC   (United States)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Braf inhibitor; Metastatic melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; B RAF KINASE V600E; CARBOPLATIN; IPILIMUMAB; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; PACLITAXEL; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; LEG PAIN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT DURATION; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; ENZYMOLOGY; GENETICS; PATHOLOGY; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; YOUNG ADULT;

EID: 84934976308     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.04.010     Document Type: Article

References (29)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Goydos JS, Mann B, Kim HJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005;200:362-70.
3. Libra M, Malaponte G, Navolanic PM, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005;4:1382-4.
4. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23:190-200.
5. Lee JT, Li L, Brafford PA, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010;23:820-7.
6. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751-9.
7. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Translat Med 2010;8:39.
8. Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-27.
9. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
10. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
11. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
12. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
13. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
14. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF and BRAF mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2000;15:323-32.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
17. Chan MM, Haydu LE, Menzies AM, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 2014;120:3142-53.
18. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015, pii: JCO.2014.56.2736. [Epub ahead of print].
19. Tirkes T, Hollar MA, Tan M, et al. Response criteria in oncologic imaging: review of traditional and new criteria. RadioGraphics 2013;33:1323-41.
20. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
21. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109.
22. Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8.
23. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9.
24. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
25. Long GV, Stroyakovsky DL, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014;371:1877-88.
26. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-9.
27. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76.
28. Hauschild A, Grobb J, Demidov L, et al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Ann Oncol 2014;25(Suppl. 4):iv378.
29. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015, pii: S0149-2918(15)00088-0. [Epub ahead of print].